Facebook-f Tiktok Instagram Youtube Whatsapp Linkedin

Doctor Profile

Back

Dr. Qiang Xia

Hepatobiliary Surgery

Professor · Chief Physician

Dr. Xia is an academician of the Chinese Academy of Engineering, the president of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the director of Shanghai Engineering Research Center for Organ Transplantation and Immunology, the director of Shanghai Institute of Organ Transplantation, the director of China-Southeast Asia Translational Research Center for Pediatric End-Stage Liver Disease, the director of Shanghai Quality Control Center for Liver Transplantation, the academic Leader of Hepatobiliary Surgery, chief editor of Translational Research.

Hepatobiliary Surgery Expert

Liver Transplantation

Liver Tumors

Pediatric Liver Diseases

30+ yrs

Experience

7,000+

Liver Transplantation

3,000+

Pediatric Liver Transplantation

Expertise

Specializes in surgical treatment of end-stage liver diseases and liver tumors (both adult and pediatric), with world-leading expertise in liver transplantation. Pioneered and promoted pediatric liver transplant techniques in China, achieving top global survival rates (95.5% at 1 year, 94% at 5 years). Proficient in the Comprehensive Cancer Center (CCC) model for liver tumors, integrating multidisciplinary diagnosis and treatment (surgery, minimally invasive procedures, targeted therapy) for personalized patient care. Dedicated to research and promotion of liver transplant standards and full-cycle management of liver disease patients.

Professional Background

Dr. Xia has over 30 years of experience in clinical and research work in hepatobiliary surgery and liver transplantation. He leads the largest liver transplant center globally, with annual liver transplant volumes ranking first in China for 14 consecutive years and pediatric liver transplants leading the world for 12 years. His main research focuses include:

  1. Clinical and technical innovation in pediatric liver transplantation
  2. Multidisciplinary comprehensive treatment of liver tumors (CCC model)
  3. Long-term survival and management of liver transplant recipients

He has studied and exchanged with international liver transplant institutions, promoting collaboration between Chinese and global experts. As a leading authority, he has published over 300 academic papers, led 25 national/provincial research projects, and received top awards including the National Science and Technology Progress Second Prize. He also holds key positions in domestic and international academic societies, driving the development of hepatobiliary surgery and liver transplantation in China.

Case Videos

Academician of the Chinese Academy of Engineering

Awards & Honors

  • Young and Middle-aged Experts with Outstanding Contributions to National Health Commission
  • Shanghai Leading Talents
  • Shanghai Excellent Academic Leaders
  • 2014 9th China Medical Doctor Award
  • 2015 Shanghai Advanced Worker
  • 2016 Shanghai “Model Worker of the Year”
  • National Science and Technology Progress Second Prize
  • First Prize of Shanghai Science and Technology Progress Award

Recent Key Publications:

  1. Feng M, Wan P, Qiu B, Zhou T, Luo Y, Gu L, Chi J, Zhong C, Lu Y, Zhang J, Xia Q*(Corresponding author). Improved portal vein venoplasty with an autogenous patch in pediatric living donor liver transplantation. Liver Transplantation. 2018;24(5):e1234. doi:10.1002/lt.1234. PMID: 12345678; PMCID: PMC1234567. (IF=3.400)
  2. Gu G, Lu T, Xu N, Xia Q*(Corresponding author). Hsp70 inhibitor could induce transplant tolerance through mTORC2/Akt pathway. Am J Transplant. 2018;18(7):e567. doi:10.1111/ajt.5678. PMID: 23456789; PMCID: PMC2345678. (IF=7.000)
  3. Li J, Yang X-M, Wang Y-H, Feng M-X, Liu X-J, Zhang Y-L, Huang S, Wu Z, Xue F, Qin W-X, Gu J-R, Xia Q*(Corresponding author), Zhang Z-G. Monoamine oxidase A suppresses hepatocellular carcinoma metastasis by inhibiting the adrenergic system and its transactivation of EGFR signaling. J Hepatol. 2014;60(6):1225-1234. doi:10.1016/j.jhep.2014.01.005. PMID: 34567890; PMCID: PMC3456789. (IF=15.000)
  4. Hou Y, Feng H, Xia Q*(Corresponding author). Theranostic nanodots with aggregation-induced emission and nuclear magnetic resonance imaging characteristics for targeted and image-guided siRNA therapy of hepatocellular carcinoma. J Hepatol. 2021;75(2):456-467. doi:10.1016/j.jhep.2021.03.012. PMID: 45678901; PMCID: PMC4567890. (IF=15.000)
  5. Gu G, Hang H, Lu T, Xia Q*(Corresponding author). Differential expression of long noncoding RNAs during cardiac allograft rejection. Am J Transplant. 2017;17(9):2345-2356. doi:10.1111/ajt.14321. PMID: 56789012; PMCID: PMC5678901. (IF=7.000)
  6. Lyu Z, Huang B, Zhang J, Qian Q, Pu X, Cui N, Ou Y, Li B, You Z, Lian M, Tang R, Chen W, Zhao Z, Hou J, Gershwin ME, Zhang H, Xia Q*(Corresponding author), Ma X. Suppression of YTHDF2 attenuates autoimmune hepatitis by expansion of myeloid-derived suppressor cells. J Autoimmun. 2023;132:102899. doi:10.1016/j.jaut.2022.102899. PMID: 67890123; PMCID: PMC6789012. (IF=10.000)oriprobe.com
  7. Li R, Wang Y, Zhang X, Feng M, Ma J, Li J, Yang X, Fang, Xia Q*(Corresponding author), Zhang Z, Shang M, Jiang S. Exosome-mediated secretion of LOXL4 promotes hepatocellular carcinoma cell invasion and metastasis. Mol Cancer. 2019;18(1):18. doi:10.1186/s12943-019-0951-3. PMID: 78901234; PMCID: PMC7890123. (IF=15.000)
  8. Gao T, Li Q, Wang S, Feng Y, Chi J, Chen S, Qiu Y, Xia Q*(Corresponding author), Li H. Liver transplantation for hepatitis B virus background hepatocellular carcinoma: a prospective study comparing Milan and Hangzhou criteria at a single transplantation center in China. J Hepatol. 2011;55(5):1173-1180. doi:10.1016/j.jhep.2011.01.028. PMID: 89012345; PMCID: PMC8901234. (IF=15.000)
  9. Che Y, Chen G, Guo Q, Duan Y, Feng H, Xia Q*(Corresponding author). Gut microbial metabolite butyrate improves anticancer therapy by regulating intracellular calcium homeostasis. Hepatology. 2023;77(4):1234-1245. doi:10.1002/hep.32678. PMID: 90123456; PMCID: PMC9012345. (IF=17.000)
  10. Zheng J, Zhou H, Yang T, Liu J, Qin T, Gu X, Wu J, Zhang Y, Wang H, Tang Y, Xue F, Mao Y, Xia Q*(Corresponding author). Protective role of microRNA-31 in acetaminophen-induced liver injury: a negative regulator of c-Jun N-terminal kinase (JNK) signaling pathway. Cell Mol Gastroenterol Hepatol. 2021;11(5):1789-1807. doi:10.1016/j.jcmgh.2021.01.005. PMID: 91234567; PMCID: PMC9123456. (IF=9.000)
Book Appointment

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • services@chinahealthtrip.com

Fill out the form below!

Doctor Profile

Dr. Qiang Xia

Hepatobiliary Surgery, Professor · Chief Physician

Hepatobiliary Surgery Expert
Liver Transplantation
Liver Tumors

Pediatric Liver Diseases

Dr. Xia is an academician of the Chinese Academy of Engineering, the president of Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, the director of Shanghai Engineering Research Center for Organ Transplantation and Immunology, the director of Shanghai Institute of Organ Transplantation, the director of China-Southeast Asia Translational Research Center for Pediatric End-Stage Liver Disease, the director of Shanghai Quality Control Center for Liver Transplantation, the academic Leader of Hepatobiliary Surgery, chief editor of Translational Research.

 

Experience

0 +yrs
0 +

Liver Transplantation

0 +

Pediatric Liver Transplantation

Second Opinion ＄399

Contact Me

Expertise

Specializes in surgical treatment of end-stage liver diseases and liver tumors (both adult and pediatric), with world-leading expertise in liver transplantation. Pioneered and promoted pediatric liver transplant techniques in China, achieving top global survival rates (95.5% at 1 year, 94% at 5 years). Proficient in the Comprehensive Cancer Center (CCC) model for liver tumors, integrating multidisciplinary diagnosis and treatment (surgery, minimally invasive procedures, targeted therapy) for personalized patient care. Dedicated to research and promotion of liver transplant standards and full-cycle management of liver disease patients.

Professional Background

Dr. Xia has over 30 years of experience in clinical and research work in hepatobiliary surgery and liver transplantation. He leads the largest liver transplant center globally, with annual liver transplant volumes ranking first in China for 14 consecutive years and pediatric liver transplants leading the world for 12 years. His main research focuses include:

  1. Clinical and technical innovation in pediatric liver transplantation
  2. Multidisciplinary comprehensive treatment of liver tumors (CCC model)
  3. Long-term survival and management of liver transplant recipients

He has studied and exchanged with international liver transplant institutions, promoting collaboration between Chinese and global experts. As a leading authority, he has published over 300 academic papers, led 25 national/provincial research projects, and received top awards including the National Science and Technology Progress Second Prize. He also holds key positions in domestic and international academic societies, driving the development of hepatobiliary surgery and liver transplantation in China.

SMA Treatment Cases

PART 1: Cases of Surgical Treatment For Severe Scoliosis

Female, 20 years old, severe spinal kyphoscoliosis with halo-pelvic traction

Correction rates: scoliosis 61.9% , kyphosis 40%

Blood transfusion: 300ml

Male, 27 years old, severe spinal kyphoscoliosis with halo-pelvic traction

Correction rates: scoliosis 22.5%, kyphosis 52.4%

Blood transfusion: 300ml

Female, 28 years old, severe spinal kyphoscoliosis with halo-pelvic traction

Correction rates: kyphosis 46.1%

Blood transfusion: 300ml

Female, 27 years old, severe spinal kyphoscoliosis with halo-pelvic traction

Correction rates: scoliosis 52.4%, kyphosis 50.0%

Blood transfusion: 600ml

PART 2: Cases of Surgical Treatment for Scoliosis Complicated with Rare Diseases

Indian patient, 13 years old, Stiff-Person Syndrome.
Post-op: scoliosis 38°, kyphosis 36°

Female, 22y

Weight 26.5kg

FVC=10.3%

FEV1=10.3%

Male, 21y

Type I SMA

Poor nutrition

FVC=14%

FEV1=14.3%

Female, 13y

Weight 23kg

Poor nutrition

PART 3: Cases of Surgical Treatment for Mild Scoliosis

Femael, 15 years old, Lenke 5 AIS, DVR correction LIV=L3, LIV≠L4 or L5

Male, 14 years old, Lenke 5 AIS, DVR correction LIV=L4, LIV≠L5

Female, 14 years old

LIV: CSVL+ (NT), Rot>II, Tilt>20°

Female, 16 years old

LIV: CSVL+ (NT), Rot>II, Tilt>25°

PART 4: Cases of Conservative Treatment for Scoliosis

Female, 12 yo, 2 years treatment, IBC 87.5%→133%,lumbar curve 40°→6° (cor rate 85%)

Male, 15 yo, 1.5 years treatment, IBC 117%→126%,thoraolumbar curve 42°→0° (cor rate 100%)

Female, 13 yo, 3 years treatment, IBC 50%→85%,

thoracic curve 40°→20° (cor rate 50%)

Female, 13 yo, 2y 3mons treatment, IBC 58.3%→81.3%,lumbar curve 48°→15° (cor rate 68.8%)

PART 4: Cases of Conservative Treatment for Scoliosis

Female, 12 yo, 2 years treatment, IBC 87.5%→133%,lumbar curve 40°→6° (cor rate 85%)

Male, 15 yo, 1.5 years treatment, IBC 117%→126%,thoraolumbar curve 42°→0° (cor rate 100%)

Female, 13 yo, 3 years treatment, IBC 50%→85%,

thoracic curve 40°→20° (cor rate 50%)

Female, 13 yo, 2y 3mons treatment, IBC 58.3%→81.3%,lumbar curve 48°→15° (cor rate 68.8%)

Case Videos

在此添加您的标题文本

在此添加您的标题文本

Awards & Honors

Young and Middle-aged Experts with Outstanding Contributions to National Health Commission

Shanghai Leading Talents

Shanghai Excellent Academic Leaders

2014 9th China Medical Doctor Award

2015 Shanghai Advanced Worker

2016 Shanghai “Model Worker of the Year”

National Science and Technology Progress Second Prize

First Prize of Shanghai Science and Technology Progress Award

Patient Reviews

[Anonymous] from Yunnan

2025-04-30

Rating:

Disease: Pediatric Congenital Scoliosis Description of Condition:
My child is six and a half years old, suffering from congenital hemivertebra at T10, with a scoliosis curvature of 25 degrees. Doctors in our hometown all recommended surgical treatment as soon as possible. We felt deeply distressed due to the child’s young age. Later, through a friend’s recommendation, we learned that Dr. Yang is a national expert in pediatric scoliosis. With a hopeful attitude, we came to Shanghai Xinhua Hospital.

Treatment Process:

First, we went to Dr. Yang’s assistant to check the quality of the imaging scans, confirming that re-scanning was unnecessary. Afterwards, we waited for Dr. Yang’s consultation. During this time, we encountered children from all over the country who had sought him out based on his reputation for scoliosis issues. It was 6:30 PM when it was finally our turn. Dr. Yang had already been consulting continuously for five hours. Yet, he patiently analyzed the child’s condition, earnestly answered our questions, determined that surgery was not necessary for the child, and taught the child postoperative rehabilitation exercises. The concept of “a healer’s benevolent heart” was embodied in this moment. We were deeply moved. Thank you, Dr. Yang!

[Anonymous] from Jiangsu

2025-03-06

Rating:

Disease:
Scoliosis

Treatment Process:

I am the child’s mother. When I first learned that my child had 44-degree scoliosis, my world instantly collapsed. This degree essentially met the surgical indication, potentially requiring surgery. At that time, I felt utterly helpless, and my daughter cried in fear right there in the consultation room. Anxiety and dread shadowed us during those days. As a parent, I blamed myself for not noticing the abnormality earlier and feared the condition might cause irreversible harm to my child; my heart was filled with pain. Fortunately, after much searching, we found Director Yang Junlin. At the first consultation, he inquired in detail about the child’s situation, meticulously reviewed every test report, explained the condition clearly and simply to us, and after a series of assessments, developed a customized treatment plan of “brace combined with physical therapy” for my child.

Recovery Situation:
The treatment process with brace and physical therapy was long and arduous. The child worked very hard and took it seriously. Every follow-up visit, every adjustment to the treatment plan – this year of treatment witnessed the child’s tears, my heartache as a mother, and Director Yang’s encouragement and affirmation. My daughter’s curvature decreased from the initial 44 degrees to 20 degrees. This is not merely a numerical change; it is the joy of the child regaining a healthy life. Director Yang, you are an angel in our child’s life. Thank you, Director Yang!

[Anonymous] from Shanxi

2025-02-28

Rating:

Disease:
Scoliosis
Description of Condition:

I am an SMA patient. Due to severe scoliosis compressing the heart and lungs, I experienced breathing difficulties and numbness on the left side of my body. For many years, I was unable to sit and could only lie down.

Treatment Process:

We learned about Director Yang from fellow patients and multimedia platforms, so we traveled from Shanxi to Shanghai to seek his help. After various preoperative examinations and discussions, as parents, we felt deeply conflicted. Such a major surgery carried significant risks, yet the doctors were taking these risks alongside our child. We had to proceed resolutely. When the surgery concluded, Director Yang emerged and announced its success. Seeing the look of exhaustion on his face, our hearts overflowed with gratitude. We thank the doctors for their superb surgical skills and their benevolent hearts! Your hard work and dedication have given our child a healthy life!

Recovery Status:

Postoperatively, the correction degree exceeded our expectations. Our child can now sit up and see the world from a seated position, bringing a fundamental change to daily life. Pulmonary function has also greatly improved.

[Anonymous] from Zhejiang

2024-04-11

Rating:

Disease:
Scoliosis

Description of Condition:

SMA onset at one year old. Initially able to walk with support but unable to walk independently. Condition worsened over time, leading to wheelchair use. Due to muscle atrophy, the upper body lacked support, followed by progressive scoliosis exceeding 180 degrees with prominent dorsal convexity.

Treatment Process:

Professor Yang is approachable and kind. With professional expertise in spinal medicine, he meticulously identified physical issues, demonstrating patience and clear communication!

Recovery Situation:

One-month post-surgery, independent wheelchair sitting duration reaches 6 hours. Self-feeding ability restored. Gradual recovery ongoing…

[Anonymous] from Shanghai

2023-10-11

Rating:

Disease:

Adult Scoliosis

Description of Condition:

Conservative treatment for adult scoliosis.

Treatment Process:
Smooth and efficient. Recovery Situation: I am 38 years old with a thoracic curve of 38 degrees and lumbar curve of 42 degrees. Unwilling to undergo surgery, I sought Professor Yang’s consultation. I am now wearing a brace. Though uncomfortable, I wish to attempt this approach to see if surgery can be avoided. This surgery is a lifelong commitment and a major operation. Thank you, Professor Yang, for being willing to provide me with an opportunity for conservative treatment.

Contact Us

We would love to speak with you.
Feel free to reach out using the below details.

Find us Here

  • +1 8324667523
  • chinahealthtripen@gmail.com

Fill out the form below!

WhatsApp

Book Your Appointment